Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Nasaruplase Gamma · LTI-01

Recombinant protein · Activator of fibrin · developed by Rein Therapeutics

Phase 2 Most advanced trial (none active)

RNTX Developer

1 Registered trials

What is Nasaruplase Gamma?

Nasaruplase gamma is a recombinant single-chain urokinase plasminogen activator (scuPA) administered intrapleural to break down fibrinous adhesions and promote drainage of pleural fluid. It is studied in complicated parapneumonic pleural effusion and empyema.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: LTI-01
Drug type: Recombinant protein
Targets: fibrin
Mechanism: Activator of fibrin
Pathways: fibrinolysis
Therapy area: Respiratory
Developer: Rein Therapeutics (RNTX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 66522BCB6P

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04159831	Phase 2	Pleural Effusion	Completed	RNTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pleural Effusion

More from Rein Therapeutics

LTI-03 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the RNTX page.

Follow RNTX, the company behind Nasaruplase Gamma

See RNTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RNTX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z